GSK-461364isaninhibitorofpolo-likekinase1(PLK1)thatiscurrentlyinclinicaltrialsasapotentialtreatmentforsolidtumorcancers.GSK-461364displaysanticancerchemotherapeuticactivityaswellasanticoagulantactivity.Thiscompoundinhibitsglioblastomacellproliferation,invasion,andcolonyformationandinducesapoptosisandG2phasecellcyclearrest.
| CasNo. | 929095-18-1 |
|---|---|
| Purity | ≥99% |
| Formula | C27H28F3N5O2S |
| FormulaWt. | 543.60 |
| IUPACName | 5-{6-[(4-Methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl}-3-{(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy}-2-thiophenecarboxamide |
| Appearance | Whitetooffwhitepowder |
| StoreTemp | -20°C |
|---|---|
| ShipTemp | Ambient |
| InfoSheet | G7241InfoSheetPDF |
|---|
YimH.Currentclinicaltrialswithpolo-likekinase1inhibitorsinsolidtumors.AnticancerDrugs.2013Nov;24(10):999-1006.PMID:23949254.
PezukJA,BrassescoMS,MoralesAG,etal.Polo-likekinase1inhibitioncausesdecreasedproliferationbycellcyclearrest,leADIngtocelldeathinglioblastoma.CancerGeneTher.2013Sep;20(9):499-506.PMID:23887645.
OlmosD,BarkerD,SharmaR,etal.PhaseIstudyofGSK461364,aspecificandcompetitivePolo-likekinase1inhibitor,inpatientswithadvancedsolidmalignancies.ClinCancerRes.2011May15;17(10):3420-30.PMID:21459796.
